Start free trial
Markets US Stocks Health Technology Medical Specialties

Lantheus Holdings, Inc

LNTH NASDAQ
LNTH
Lantheus Holdings, Inc NASDAQ
See more on the world's #1 chartsSee more on the world's #1 charts
 
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on the world's #1 chartsSee more on the world's #1 charts
Overview
Ideas Financials Technicals

LNTH Stock Chart

Ideas

Videos only
LNTH Receives FDA Approval of PYLARIFY
LNTH
, 240
LNTH: LNTH Receives FDA Approval of PYLARIFY

NASDAQ:LNTH

$LNTH can rise in the next days
LNTH
, 30
Long
LNTH: $LNTH can rise in the next days

Contextual immersion trading strategy idea. Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. The demand for shares of the company looks higher than the supply. This and other conditions can cause...

LANTHEUS HOLDINGS POSSIBLE SUPPORT TO RESTART
LNTH
, 1W
Long
LNTH: LANTHEUS HOLDINGS POSSIBLE SUPPORT TO RESTART

In my opinion the coincidence of the SMA 200 weekly with the 50% of Fibonacci level, as well as the RSI level under 20, is a nice opportunity to enter at the level around 16,00. I will put my stop loss around 5% than 16,00. The enigma about this correction is if is a 2 or an A wave! Go ahead

LNTH: Ready for 40%–90% value drop
LNTH
, 1M Short
LNTH: LNTH: Ready for 40%–90% value drop

– No interconnectable formations within main formation – No leg since mid 2016 (extremely bearish), must return to lower trend line – Significant volume drop (below average), sharp corrections expected – Unbroken PSAR series from 2016 to 2018 will now be mirrored in a down trend – 8 out of 9 indicators point to much lower stock value, 1 'neutral Very straight...

ValuEngine upgrades $LNTH to a BUY rating
LNTH
, D
Long
LNTH: ValuEngine upgrades $LNTH to a BUY rating

ValuEngine Forecast Models 1-Month 26.51 0.51% 3-Month 27.11 2.76% 6-Month 27.91 5.79%

lnth testing main trendline
LNTH
, D
Long
LNTH: lnth testing main trendline

trend line setup

Lantheus - Swing opportunity
LNTH
, D
LNTH: Lantheus - Swing opportunity

Strong channel, clear support. Good for a swing.

Lantheus Holdings Inc - Be careful $LNTH
LNTH
, D
LNTH: Lantheus Holdings Inc - Be careful $LNTH

$LNTH Not making higher highs, potential triple-top

Bullish & Low Risk
LNTH
, D
Long
LNTH: Bullish & Low Risk

Watch for LNTH to make a move back up to past resistance around $9.70, Price has just broken above the resistance line and it is also just above the 50ma which has been acting as a dynamic support for quite some time. Also volume has been increasing, MACD looks like it is soon going to crossover and the Squeeze Momentum indicator is currently bullish.

LNTH flat base brake out
LNTH
, D
Long
LNTH: LNTH flat base brake out

stalking LNTH for a break above recent daily highs, looking for a move into new ATH's as it leaves this nice and flat base

$LNTH trend play
LNTH
, 240
Long
LNTH: $LNTH trend play

Befriend the Trend.

$LNTH buy buy buy
LNTH
, 60
Long
LNTH: $LNTH buy buy buy

Bull trend rising to upper R-channel line.

$LNTH buy buy buy
LNTH
, 60
Long
LNTH: $LNTH buy buy buy

Aggressive uptrend with head-fake shake out of weak hands.

LNHT: LET'S SEE IF IT FAILS BREAKING THE TOP
LNTH
, 60
LNTH: LNHT: LET'S SEE IF IT FAILS BREAKING THE TOP

LNHT seems topping on 4h and daily chart, failing 2 times on breaking the top. If it fails for the third time the drop will be huge, otherwise it is the beginning of a strong wave to the upside. Let's see how it develops.

Breaking Out
LNTH
, D
LNTH: Breaking Out

Watch the 3.25 and 3.5 levels for continued breakout

Technicals

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Medical Specialties
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes, and assist clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment operations offers direct distribution in Canada and Puerto Rico; third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America; and EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.

Breaking news